Amtagvi

Mar 06, 2026

Summary Iovance’s AMTAGVI has become the first personalized TIL therapy to receive regulatory clearance, gaining accelerated FDA approval for use in advanced melanoma following PD-1 inhibitor treatment. AMTAGVI approval has sparked intensified activity across the field, with companies such as Obsidian Therap...

Feb 20, 2026

Summary  TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled, broadening options beyond PD-1 and BRAF/MEK inhibitors for metastatic melanoma, and driving extensive clinical evaluation across NSCLC, HNSCC, CRC, pancreatic, prosta...

Feb 26, 2024

The category of T-cell therapy, which revolutionized the management of specific blood cancers, has now extended its impact to solid tumor treatment with the approval from the FDA of a groundbreaking immunotherapy pioneered by Iovance Biotherapeutics. Known as Amtagvi or lifileucel, this medication marks the debut o...